5-fluorouracil (5-FU) as adjuvant chemotherapy in Duke's stage C colorectal cancer
Bliss E, Robert G
Record ID 31998008877
The authors examine how worthwhile is the proposal that all patients with Duke's stage C colorectal cancer be offered 5-fluorouracil (5-FU) as adjuvant chemotherapy following surgery.
Authors' results and conclusions: 100 patients given 5-FU/FA would be expected to gain 24 life years compared with respective patients randomised to receive surgery alone. The results for 5-FU/levamisole were similar (23 life years gained).
Authors' recomendations: There are undoubted benefits, but in view of side effects the cost of QALYs is likely to be at the upper end of the range.
Authors' methods: Review
Project Status: Completed
URL for project: http://www.wihrd.soton.ac.uk
Year Published: 1996
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Chemotherapy, Adjuvant
- Costs and Cost Analysis
- Colorectal Neoplasms
Organisation Name: Wessex Institute for Health Research and Development
Contact Address: Pauline King. Wessex Institute for Health Research and Development, Boldrewood Medical School, Bassett Crescent East, Highfield, Southampton. SO16 7PX Tel. +44 1703 595661 Fax +44 1703 595662
Copyright: Wessex Institute for Health Research and Development (WIHRD)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.